心脏T2* mapping评估终末期肾病患者心肌铁缺乏及有效心脏铁管理策略探索
研究纳入59例透析患者(30例口服铁剂腹膜透析、29例静脉铁剂血液透析)和30例健康对照,用3.0T心脏MRI T2* mapping定量心肌铁。透析患者整体心脏T2*高于健康对照,腹膜透析患者整体及前间隔T2*高于血液透析患者,整体T2*与LVEF及左室应变负相关;作者认为静脉铁剂可能是血液透析依赖终末期肾病患者有效的心脏铁管理策略。
要点
- 透析患者整体心脏T2*值高于健康对照(27.1±6.29 ms vs 24.6±3.60 ms,p<0.05)。
- 腹膜透析患者整体心脏T2*值高于血液透析患者(28.5±4.30 ms vs 25.x7±3.54 ms,p<0.05)。
- 整体T2*值与LVEF、峰值径向应变、周向应变及纵向应变成负相关。
核心结论
- 腹膜透析患者尽管接受口服铁剂治疗,与接受静脉铁剂治疗的血液透析患者相比仍存在心肌铁缺乏。
- 心脏T2*值是LVEF和左室机械力学改变的独立危险因素和预测因子。
- 静脉铁剂可能是血液透析依赖终末期肾病患者有效的心脏铁管理策略。
研究设计与样本
- 研究纳入59例透析患者,包括30例接受口服铁剂治疗的腹膜透析患者和29例接受静脉铁剂补充的血液透析患者,另设30例健康对照。
- 采用3.0T心脏MRI,序列包括cine、T2 stir和T2* mapping。
- 定量T2* mapping和cine图像分析由两名放射科医师使用cvi42完成。
关键影像表现/征象
- 透析患者整体心脏T2*值高于健康对照(27.1±6.29 ms vs 24.6±3.60 ms,p<0.05)。
- 腹膜透析患者整体心脏T2*值高于血液透析患者(28.5±4.30 ms vs 25.x7±3.54 ms,p<0.05)。
- 腹膜透析患者前间隔心脏T2*值高于健康对照(32.0±4.49 ms vs 27.8±4.02 ms,p<0.05)。
诊断标准与关键数值
- 整体心脏T2*值在透析患者为27.1±6.29 ms,健康对照为24.6±3.60 ms。
- 整体心脏T2*值在腹膜透析患者为28.5±4.30 ms,血液透析患者为25.x7±3.54 ms(原文此处写作25.x7,表述有误)。
- 前间隔心脏T2*值在腹膜透析患者为32.0±4.49 ms,健康对照为27.8±4.02 ms。
临床应用与阅片要点
- 心脏T2* mapping可用于评估终末期肾病透析患者的心肌铁含量。
- 整体T2*值与LVEF、峰值径向应变、周向应变及纵向应变成负相关,提示其与左室功能和机械力学改变相关。
- 作者认为静脉铁剂可能是血液透析依赖终末期肾病患者有效的心脏铁管理策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To explore myocardial iron content using Cardiac T2* Mapping in dialysis patients undergoing oral iron therapy or intravenous iron supplements compared to healthy controls.
METHODS: Fifty-nine dialysis patients, including 30 peritoneal dialysis (PD) patients who underwent oral iron therapy, 29 hemodialysis (HD) dialysis patients who underwent intravenous iron supplements, and 30 healthy controls were included in the study. Cardiac MRI, including cine, T2 stir, and T2* mapping, was conducted at 3.0T. Quantitive T2* mapping, Cine imaging analysis was performed by two radiologists using cvi42.
RESULTS: The global cardiac T2* value was higher in dialysis patients than in healthy controls (27.1 ± 6.29 ms versus 24.6 ± 3.60 ms, p< 0.05). The global cardiac T2* value of PD patients was higher than that of HD patients (28.5 ± 4.30 ms versus 25.x7 ± 3.54 ms, p< 0.05). The anteroseptal cardiac T2* value was higher in PD patients than in healthy controls (32.0 ± 4.49 ms versus 27.8 ± 4.02 ms, p< 0.05). The global T2* value negatively correlated with left ventricular ejection fraction (LVEF), peak radial strain, circumferential strain, and longitudinal strain.
CONCLUSION: Our study confirmed that PD patients have myocardial iron deficiency despite undergoing oral iron therapy compared to HD patients who received intravenous iron treatments. And the Cardiac T2* value was found to be an independent risk factor and predictor of LVEF and left ventricular altered mechanics. Intravenous iron supplements may be an effective cardiac iron management strategy in patients with HD-dependent end-stage renal disease.
引用
- Zhou H, Wei Y, An DA, et al. Myocardial Iron Deficiency Quantification and Effective Cardiac Iron Management Strategy Exploration evaluated by Cardiac T2* Mapping in End-Stage Renal Disease Patients. Acad Radiol. 2020. PMID: 32402784. doi:10.1016/j.acra.2020.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。